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Objectives The aim of our study was to compare coronary vasomotion after implantation of a second-generation biolimus
A9-eluting stent (BES) and of a sirolimus-eluting stent (SES).
Background Drug-eluting stents (DES) have been associated with impaired local coronary vasomotion, delayed endothelializa-
tion, and increased late thrombotic risk. New DES with different drugs, pharmacokinetics, and polymers have
been developed.
Methods Nineteen patients with a BES and 15 patients with a SES were studied 9 months after stent implantation.
Endothelium-dependent and -independent coronary vasomotion were tested proximally and distally to the stent
as well as at a reference segment during right atrial pacing at increasing heart rates. Quantitative coronary
angiographic measurements were performed offline.
Results Of the patients with BES, 2 showed vasoconstriction with increased heart rate and 17 showed vasodilatation. Of
the patients with a SES, 9 showed vasoconstriction while 6 showed vasodilatation. The SES showed significant
vasoconstriction at both the proximal (2.3  10% vs. 7.9  10%) and the distal (5.4  9% vs. 6.1  8%)
segments to the stent compared with the BES (p  0.003 for proximal, p  0.001 for distal segment).
Endothelium-independent vasomotion after intracoronary nitrates did not differ significantly between the
2 groups (p  NS for proximal and distal segment).
Conclusions Unlike the case with the SES, endothelium-dependent vasomotion at adjacent stent segments seems to be pre-
served after BES implantation. This result may be explained by the different drug release kinetics, DES design,
or characteristics of polymer used in the stent system. (J Am Coll Cardiol 2008;51:2123–9) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.059a
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rrug-eluting stents (DES) are considered a breakthrough
n the treatment of coronary artery disease because of their
bility to reduce rates of early restenosis and subsequent
eed for target lesion reintervention. However, delayed
ealing has been associated with an increased risk of late and
ery late stent thrombosis (1–3). Moreover, paradoxical
oronary vasoconstriction at coronary segments adjacent to
he stent has been reported for both sirolimus-eluting stents
SES) and paclitaxel-eluting stents (PES) up to 12 months
fter implantation (4–7). This observation may be attribut-
rom the *Cardiovascular Centre, Aalst, Belgium; †Department of Cardiology,
niversity Institute for Cardiovascular Diseases, Clinical Center of Serbia, Belgrade,
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Ministry of Health of Serbia, Belgrade, Serbia. Dr. Hamilos is supported by a
ellenic Society of Cardiology fellowship.r
Manuscript received October 8, 2007; revised manuscript received November 20,
007, accepted December 8, 2007.ble to delayed endothelialization caused by the drug and/or
ndothelial dysfunction caused by polymer-induced inflam-
ation or hypersensitivity reaction. New DES have been
eveloped with different stent designs, drugs, and polymers.
obori (Terumo Corporation, Tokyo, Japan) is one such
econd-generation DES that uses a bioresorbable polymer
polylactic acid) from which biolimus A9, an analogue of
irolimus, is eluted.
See page 2139
The aim of our study was to asses the endothelium-
ependent and -independent coronary vasomotion 9
onths after either biolimus A9-eluting stent (BES) or
ES implantation, using right atrial pacing at increasing
ate steps. Cardiac pacing increases myocardial oxygen
equirements to be matched by augmented coronary blood
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Endothelium and DES June 3, 2008:2123–9flow. The resulting increase in
shear stress dilates human coro-
nary epicardial arteries in the
presence of functional endothe-
lium. Endothelial cell dysfunc-
tion and the subsequent reduced
nitric oxide activity are associated
with paradoxical constriction of
epicardial arteries with cardiac
pacing (8–11).
Methods
atients with BES (n  24) and with SES (n  19) having
esions treated with a single stent and who consented to the
tudy protocol were included in the study. All of them
nderwent follow-up coronary angiography 9  1 months
fter stent implantation as a part of the NOBORI CORE
tudy. The NOBORI CORE study is a prospective, mul-
icenter, comparative study of Nobori and Cypher DES
ystems in which all patients were scheduled to undergo
ngiographic follow-up. The primary end point was angio-
raphic in-stent late loss at 9 months post-procedure. The
ain secondary end points were major cardiac adverse event
ate at 1 and 9 months and yearly up to 5 years as well as
ssessment of endothelial function by atrial pacing at 9
onths. The NOBORI CORE study was conducted in 5
tudy sites, but endothelial function assessment was planned
n only 2 sites enrolling the largest number of patients. All
atients consented to undergo the study protocol, which was
pproved by the local ethics committee.
All stents were implanted in de novo lesions. Two
atients (1 in the BES and 1 in the SES group) with
ngiographically significant in-stent restenosis were ex-
luded from the study protocol. In 2 patients from each
roup the quality of angiography was not sufficient to allow
ccurate measurement of vessel diameter changes, and those
atients were also excluded. Finally, excluded from the
nalysis were patients having constriction of the reference
essel (2 in the BES group and 1 in the SES group).
tudy protocol. All vasoactive drugs were discontinued at
east 24 h before catheterization except for sublingual
itroglycerin, which was withheld for at least 1 h. Long-
cting beta-blockers were stopped 48 h before study.
Diagnostic left heart catheterization and coronary arte-
iography were performed by a standard percutaneous fem-
ral approach. A 6-F diagnostic catheter was introduced
nto the left main or right coronary artery, depending on the
essel studied. A 5-F bipolar pacing wire (St. Jude Medical,
t. Paul, Minnesota) was placed against the high lateral
ight atrial wall. The pacing study was then performed.
fter control conditions were established, rapid atrial pacing
as conducted at 20 beats/min above baseline heart rate for
min, followed by increments in the pacing rate of 20
eats/min for 2 min each until a final pacing rate of 150
Abbreviations
and Acronyms
BES  biolimus A9-eluting
stent(s)
DES  drug-eluting stent(s)
PES  paclitaxel-eluting
stent(s)
QCA  quantitative
coronary angiography
SES  sirolimus-eluting
stent(s)eats/min was reached, angina was produced, or atrioven- lricular Wenckebach block developed. After rapid atrial
acing, a 2-min recovery period was allowed. Intracoronary
itroglycerin (200 g total dose) was administered. Atrio-
entricular Wenckebach block was not treated with intra-
enous atropine in order not to influence coronary vasomo-
ion and blood flow responses. Pacing from the right
entricle was performed up to 150 beats/min in the patients
n whom atrioventricular Wenckebach block developed at
ates below 110 beats/min.
Serial contrast injections of the study vessel were per-
ormed at baseline, at the end of a 2-min period at each
acing rate, immediately after ending the pacing, and after
ntracoronary nitroglycerin administration. Heart rate and
lood pressure were digitally recorded during the entire
tudy protocol.
uantitative coronary angiography. Coronary angiogra-
hy was performed on a digital X-ray system (Axiomatis
SC, Siemens Medical Solutions, Malvern, Pennsylvania)
t 25 frames/s. An appropriate view that permitted clear
isualization of both the target artery and the reference
essel segment was selected. The angle of the view, the
istance from the X-ray focus to the object, and the distance
rom the object to the image intensifier were kept constant
uring the study.
The computer-based ACOM.PC 5.01 (Siemens Medical
olutions) was used for off-line quantitative coronary an-
iography (QCA) analysis. All measurements were done by
n independent observer who was blinded to the study
rotocol and type of stent implanted. Percent changes were
alculated in all patients using the baseline angiogram as
eference. In both groups, a reference angiographically
ormal segment in another vessel not related to the stented
esion as well as the stented segment and its adjacent
egments proximal and distal were assessed (at least 5 mm
p to 15 mm proximal and distal to the stent edges). If the
ntervened vessel was the right coronary artery, an angio-
raphically normal segment as far as possible from the
tented vessel segment was taken as reference. Because of
tent placement in an ostial vessel segment, the proximal
egments could not be evaluated in 4 patients in the BES
roup and in 2 patients in the SES group. All measurements
ere done exactly at the same segment, at baseline, at every
acing step, immediately after stopping pacing and after
ntracoronary nitrates. A progressive reduction in vessel
iameter was termed as vasoconstriction, and an increase as
asodilatation. Patients with vasoconstriction in the refer-
nce segment were not included in the final analysis because
hey were considered to have a generalized endothelial
isease. Normalization of vessel diameters for the maximal
asodilated state was performed by dividing resting and
acing data by the vessel diameter after nitrates administra-
ion. In our laboratory, coronary artery diameter measure-
ents performed with the ACOM.PC 5.01 (Siemens
edical Solutions) have interobserver variability of 0.11
m, and intraobserver variability of 0.08 mm for meanumen diameter on repeated analysis of the same frame.
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June 3, 2008:2123–9 Endothelium and DEStatistical analysis. Statistical analysis was performed us-
ng the SAS 9.1 software (SAS Institute Inc., Cary, North
arolina). Continuous data are summarized as mean 
tandard deviation. Unpaired or paired t test were ade-
uately used to analyze differences in continuous variables.
isher and chi-square tests were used to analyze differences
etween categorical variables. A general linear model was
erformed to adjust the vasomotor response to the baseline
arameters and to predict the vasomotor response. All
tatistical comparisons were performed at the 5% level of
ignificance.
esults
he baseline characteristics of the patients included in the
nalysis are comparable (Table 1). Mean time from implan-
ation was 9.12  1.0 months for SES and 9.9  0.9
onths for BES. In the SES group, 8 stents were implanted
n the left anterior descending artery, 5 in the left circumflex
rtery, and 2 in the right coronary artery (numbers for BES
ere 10, 3, and 6, respectively; p  NS). One patient in
ach group required right ventricular pacing because of
eveloping atrioventricular block at heart rate below 110
eats/min.
emodynamic data. Baseline and maximal pacing rate,
ean arterial pressure at baseline and at maximal pacing
ate, and rate-pressure product both at baseline and at
aximal pacing rate were similar in the 2 groups (Table 2).
ean arterial blood pressure did not change significantly
uring pacing compared with baseline in the BES group
from 95  2.9 mm Hg to 95.4  3.8 mm Hg, p  NS),
hereas it was increased significantly in the SES group
from 96  3.5 mm Hg to 101  4.5 mm Hg, p  0.011).
ean arterial pressure changes from baseline to peak pacing
ere not statistically significant between SES and BES (4.6
m Hg vs. 1.0 mm Hg, p  0.22 respectively).
oronary vasomotor response to pacing and nitrates. Mean
ata for the 2 patient groups with regard to mean vessel
atient Characteristics
Table 1 Patient Characteristics
SES
(n  15)
BES
(n  19) p Value
Age, yrs 54  8 56  9 0.55
Gender, male/female 12/3 15/4 1
Number of diseased vessels 1.7 1.6 0.81
Hypertension 13 15 0.67
Diabetes 4 4 0.67
Hyperlipidemia 14 17 1
Smoking 9 11 1
Family history of coronary artery disease 8 15 0.15
Nitrates 4 7 0.71
Angiotensin-converting enzyme inhibitors 7 9 1
Calcium-channel blockers 9 2 0.003
Statins 15 18 1
Beta-blockers 14 18 1lES  biolimus A9-eluting stent(s); SES  sirolimus-eluting stent(s).iameter of the proximal, stented, distal, and reference
egments are shown in Table 3. For the segment proximal
o the stent, normal vasomotion (vasodilatation) was main-
ained in the BES group, whereas vasoconstriction was
bserved in the SES group (7.9  10% vs. 2.3  10%,
 0.003) (Figs. 1 and 2). For the segment distal to the
tent, normal vasomotion (vasodilatation) was maintained
n the BES group, whereas vasoconstriction was observed in
he SES group (6.1 8% vs.5.4 9%, p 0.001) (Figs.
and 2). In the SES group, the vasomotor response in the
eference segment was better than in both the proximal and
he distal segments (2.3  10% for proximal and 5.4 
% for distal vs. 10  0.4% for reference, p  0.001 for
oth). In the BES group, reference segments had a higher
asodilatory response from the distal segment (6.1  8% vs.
3  0.6%, p  0.003) but not from the proximal segment
7.9  10% vs. 13  0.6%, p  NS). The stented vessel
egments in both groups showed no diameter change (Table
). The reference segment not related to the stented
egment showed pacing-induced vasodilatation in both
roups (13  0.6% in BES, 10  0.4% in SES, p  NS).
ntracoronary nitrates were associated with maximal vaso-
ilatation of all of the evaluated vessel segments (proximal,
istal, and reference) in both groups (Table 3). The maxi-
al vasodilatation observed after nitroglycerin administra-
ion was not statistically significantly different for any of the
egments between the 2 groups.
iscussion
ur study is the first to show that a newer-generation DES is
ssociated with better endothelium-dependent coronary vaso-
otor response than SES, whereas the nonendothelium-
ependent vasomotor response was preserved in all cases and
id not differ significantly between the 2 groups. These
ndings pertain only to the 2 stents under study. Despite
he similarities between biolimus and sirolimus, it is un-
nown whether our findings are related to stent, polymer, or
o a drug class effect.
ndothelial function after stent implantation. Implanta-
ion of balloon expandable stents is necessarily associated
ith vessel wall injury and trauma to the coronary endothe-
emodynamic Data
Table 2 Hemodynamic Data
SES (n  15) BES (n  19) p Value
Mean arterial blood pressure at
baseline (mm Hg)
96.9 13.9 95.1 11.9 0.71
Mean arterial blood pressure at
peak pacing (mm Hg)
101 17 95.5 16 0.36
Heart rate at baseline (beats/min) 79.1 20.3 77.5 13.9 0.8
Maximal pacing rate (beats/min) 133.1 19.7 133.7 14.2 0.91
Rate-pressure product at baseline
(mm Hg  beats/min)
10,202 4,174 10,039 2,436 0.89
Rate-pressure product at peak
pacing (mm Hg  beats/min)
15,703 3,913 15,258 3,123 0.72
bbreviations as in Table 1.ium. This trauma sets in motion the inflammatory reaction
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Endothelium and DES June 3, 2008:2123–9nd healing response that eventually leads to re-
ndothelialization. In the first month after the implantation
f a bare-metal stent, a new immature endothelial layer
overs the stent struts, reestablishing a normal coronary
essel wall lining. Autopsy studies suggest that endothelium
ecovery is complete 3 months after the implantation, but
unctionality of the neo-endothelium has not been investi-
ated (12). In a study by Maier et al. (13), coronary
asomotion after exercise testing during coronary angiogra-
hy was normal in segments distal and proximal to bare-
etal stent 6 months after implantation.
After implantation of SES, a more pronounced inflam-
atory response has been described that may occasionally be
ssociated with a local hypersensitivity reaction and eosin-
philic infiltration. The synthetic polymer containing the
Figure 1 Distribution of Diameter
Changes in Patients With BES and SES
Scatterplots showing the distribution of percent mean diameter changes from
baseline to maximal pacing rate in patients with biolimus A9-eluting stents
(BES) and sirolimus-eluting stents (SES), in proximal (A) and distal (B)
segments.drug may be an important trigger of local coronary inflam-T B M
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June 3, 2008:2123–9 Endothelium and DESation, even though the metal struts or the stent itself may
articipate in this reaction. Coronary inflammation is re-
ponsible for delayed re-endothelialization of stent and
essel wall, which eventually results in a delayed vascular
ealing response. Sirolimus impairs the normal healing
rocesses of the injured arterial wall by inhibiting endothe-
ial cell proliferation (14). In addition, sirolimus was shown
o enhance tissue factor expression in human endothelial
ells (15), and inhibits the migration and proliferation of
ndothelium progenitor cells, which may play an important
ole in endothelium regeneration (16,17). These findings
uggest that SES may impair both the endothelial regener-
tion and the ability of endothelial cells to exert their normal
unction.
Poor stent endothelialization means that stent struts are
n direct contact with blood and its elements. Human
utopsies showed insufficient endothelial coverage and de-
ayed arterial healing with SES, regardless of the delay from
mplantation (18–23). These findings are complemented by
ngioscopy (24) and optical coherence tomographic imaging
Figure 2 Mean Diameter of the Proximal, Distal, and
Reference Segments in the BES and SES Groups
Mean diameter values at baseline, maximal pacing rate, and after nitroglycerin
administration in BES and SES groups, in proximal (A), distal (B), and refer-
ence (A and B) segments. The p values for the comparison between BES and
SES are indicated for both proximal and distal segments. Abbreviations as in
Figure 1.25), which showed incomplete endothelialization and un- povered stent struts 3 to 6 months after SES implantation.
omplete or partial lack of re-endothelialization of stent
truts and vessel wall generates a long-lasting, unhealed
essel wall surface favoring platelet adhesion and aggrega-
ion, which may eventually cause thrombus formation.
ndothelial recovery and vasomotor response after BES
mplantation. All of those concerns led to new targets in
ES development with use of bioerodable polymers and
rugs specifically developed for local application. The No-
ori coronary stent system uses a bioresorbable polymer
polylactic acid) from which biolimus A9 is eluted. Biolimus
9 is a new sirolimus derivative that binds to the cytosolic
mmunophilin FK binding protein 12. The formed complex
inds to the mammalian target of rapamycin and inhibits
rowth factor-driven cell proliferation, including T-cells
nd vascular smooth muscle cells. It has the potential to
revent restenosis in coronary stents by interrupting smooth
uscle cell migration and proliferation. In addition, an
nhanced lipophilicity enables an increased uptake in local
arget tissues and reduced presence in areas surrounding the
tented segment or even in the systemic circulation.
In our study, BES showed a better-preserved endothelium-
ependent vasomotor response compared with SES. There are
everal possible explanations for this observation. Biolimus
9 is a more lipophilic drug than sirolimus, and upon
elease would quickly bind to the target lipid-rich tissue. Of
ote, drug is present only on the vessel side (abluminally),
nd as such enters into peripheral circulation only in
inimal quantities (26). This results in a more localized
ffect and less systemic drug exposure. Animal studies
howed that after BES implantation, the tissue concentra-
ion of the drug in segments 5 mm proximal and distal to
he stent edges is almost nonmeasurable (26) and stent
ndothelialization is more complete than with SES and
ES (27). In addition, SES and BES have different drug
elease kinetics: total drug content is released from the SES
ithin 60 days with more than 60% released shortly after
tent implantation (28), versus a small initial burst and
ustained simultaneous drug release and polymer degrada-
ion taking place over 6 months in the BES (26), exposing
he surrounding tissue at any given time to a lower amount
f drug. Finally, the polymer used with BES is expected to
e absorbed in a few months. Because durable polymers
ave been held responsible for some of the late adverse
vents related to SES, it is expected that the degradation of
olymer will improve arterial healing and long-term safety
f BES.
The fact that the majority of our patients with BES had
vasodilatory response to pacing is a robust indication that
unctional endothelial re-growth is almost complete 9
onths after implantation. The findings of our study give
ome promise that newer-generation DES with different
rug and polymer platforms may be more respectful of the
essel healing while remaining at least as effective (29,30).
In our study, the response of the different patients to
acing was by and large homogenous. Some patients with
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Endothelium and DES June 3, 2008:2123–9ES seemed to have a normal vasodilatory response to
acing, albeit blunted, whereas some patients with BES had
vasoconstrictive response. Because the time course of
rterial healing after DES placement may vary from patient
o patient, endothelialization was probably more complete
n some patients than in others, for reasons that are not well
nderstood. In addition, the time after stent implantation
as longer than in previous studies, which may theoretically
llow for further healing. The time course of recovery of
ndothelial function still needs to be studied systematically.
revious studies. To our knowledge there is no other
ublished study that examines coronary vasomotion after
mplantation of a newer-generation DES. On the contrary,
here are 3 published studies that all showed agreement with
ur findings that SES cause local coronary vasoconstriction
months after their implantation compared with bare metal
tents (5–7). Two of those studies (5,7) used acetylcholine
nd the third used exercise (6) to assess coronary endothelial
unction.
The more pronounced vasoconstrictive response after
ES implantation reported in those studies could be ex-
lained by the different time points at which coronary
asomotion was tested and the different methods used to
ssess vasomotion. In 2 of those studies, acetylcholine was
sed to test the endothelial function. Despite the fact that
cetylcholine infusion has been extensively used for measur-
ng coronary vasomotor response, we believe that flow-
ediated changes induced by pacing are a more physiolog-
cal stimulus than a pharmacological test for the assessment
f endothelial function.
tudy limitations. Baseline endothelial function before
tent implantation was not assessed in our study. The
ssessment of endothelial function in patients with signifi-
ant coronary lesions is not practicable, first because it is
ifficult to stop antianginal vasoactive medication before the
ntervention, and second because it is not feasible to avoid
he use of intracoronary nitrates during the procedure.
At the time of the intervention, stent assignment was not
andomized. Patient enrollment was done in waves: all
reated patients in each institution complying with inclusion
riteria were treated simultaneously with BES or SES at
re-defined study periods determined by the availability of
ES. Because the assignment of stent type was dependent
nly on the time point of study inclusion, bias with regard
o stent-type decision was minimal and has probably not
nfluenced the result.
We assessed endothelial function 9 months after both
tent implantations, and accordingly our results refer to this
pecific time point. Further studies are needed to see
hether the differences observed between the 2 stents are
till present more than 9 months after their implantation.
oreover this study cannot indicate differences in the
linical outcomes after both stent implantations, although
OBORI CORE data at 9 months show equivalence of the
stents in terms of safety, angiographic results, and clinicalfficacy (30).Calcium channel blockers were more frequently used in
he SES group. The 24-h period of interruption is long
nough for a complete washout. Moreover, the fact that the
ES group showed more vasoconstriction than the BES
roup indicates that the difference in the use of these drugs
ould not have influenced our results.
Finally, the clinical relevance of our findings remains
nknown. Local coronary vasoconstriction is only an indi-
ect sign of endothelial dysfunction, probably caused by
elayed endothelialization in the segments proximal and
istal to the stent. Delayed endothelialization in the coro-
ary vessels has been closely related to several adverse events
31), the most severe of which is thrombus generation.
ccordingly this finding could partially explain the in-
reased late thrombotic events observed with the first-
eneration DES.
onclusions
ndothelium-dependent vasomotion at adjacent stent seg-
ents seems to be better preserved after BES implantation
han SES implantation. This finding is a strong indicator of
functionally complete endothelial regeneration, a fact that
ay hold promise for reducing thrombotic events with this
tent platform.
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